Simplify Logo

Full-Time

Associate Scientist

Cell Line Engineering, Cell, Assay, And Vector Engineering

Posted on 4/1/2024

Shape Therapeutics

Shape Therapeutics

51-200 employees

Develops programmable RNA medicines using AI

Data & Analytics
Hardware
AI & Machine Learning
Biotechnology

Compensation Overview

$82k - $110kAnnually

+ Annual Target Bonus + Sign-on Bonus + Equity Grant + Relocation Bonus

Mid

Seattle, WA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor of Science degree in Neuroscience, Cell Biology, or related discipline
  • 4+ years of experience post-degree in an academic or industry laboratory setting
  • Experience culturing and differentiating primary and iPSC cell lines
  • Skilled in mammalian cell culture, transfection, and good aseptic technique
  • Stable cell line generation via viral transduction or non-viral methods
  • Cell line banking and cryopreservation
  • qPCR/ddPCR principles and analysis
  • Western blot / ELISA
  • Flow cytometry/cell sorting
  • Ability to troubleshoot and think analytically
  • Strong work ethic
  • Collaborative team player
Responsibilities
  • Follow established protocols, analyze and communicate results with supervisor
  • Contribute to experimental design
  • Assist in cell line maintenance, generation, and tissue culture
  • Use gene editing techniques to generate gene knockouts/knockins and mutations of interest
  • Perform a broad range of cell/molecular biology techniques
  • Maintain a detailed electronic laboratory notebook

Shape Therapeutics specializes in programmable RNA medicine, using artificial intelligence to analyze data for developing new treatments. Their technology, RNAfix, modifies RNA instructions to correct genetic mutations without changing DNA, while smart-sensing vector designs allow for tailored gene expression in specific cell types. The company aims to create effective and safe medicines that address the root causes of diseases, distinguishing itself by combining AI with advanced RNA technology.

Company Stage

Series B

Total Funding

$147.5M

Headquarters

Seattle, Washington

Founded

2018

Growth & Insights
Headcount

6 month growth

2%

1 year growth

15%

2 year growth

31%
Simplify Jobs

Simplify's Take

What believers are saying

  • The appointment of industry veterans like David Epstein and Todd Simpson to the board signals strong leadership and strategic direction.
  • Collaborations with major pharmaceutical companies like Roche and Otsuka highlight ShapeTX's potential for impactful partnerships and market penetration.
  • Recognition as one of Fierce Biotech's 'Fierce 15' underscores the company's promise and innovation in the biotech sector.

What critics are saying

  • The complexity of integrating AI with RNA technology could lead to unforeseen technical challenges and delays.
  • The highly competitive biotech landscape means that ShapeTX must continuously innovate to maintain its edge.

What makes Shape Therapeutics unique

  • ShapeTX leverages AI to design novel RNA therapies, setting it apart from traditional biotech firms that may not integrate advanced computational methods.
  • Their RNAfix technology, which corrects RNA without altering DNA, offers a unique approach to treating genetic disorders, unlike many gene therapies that focus on DNA modification.
  • The company's smart-sensing vector designs enable precise gene expression tailored to specific cell types, providing a level of customization that is rare in the industry.
INACTIVE